Jobs
-
Inhaler filling experts Harro Höfliger have announced a number of management changes after the retirement of its founder, Harro Höfliger, who has been succeeded by his son, Markus Höfliger as Chairman of the Supervisory Board.… Read more . . .
-
MannKind Corporation has announced that it will offer Afrezza inhaled insulin directly to diabetes patients in the US and is also introducing a savings card program for US patients with commercial insurance . The direct… Read more . . .
-
US-based StellaPharma has announced that it will acquire G2B Pharma (G2B) and its dry powder nasal formulation of epinephrine for the treatment of anaphylaxis. According to a 2014 press release, G2B had licensed SNBL’s nasal… Read more . . .
-
Nanoform, which recently announced construction of a new GMP manufacturing facility in Helsinki, has announced the appointment of Niklas Sandler as Chief Technology Officer. Sandler was most recently Vice Rector responsible for Research Affairs and… Read more . . .
-
Glenmark Pharmaceuticals will receive an upfront payment, milestones, and royalties from Yuhan Corporation as part of a deal that gives Yuhan rights to commercialize Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray for the treatment of seasonal… Read more . . .
-
According to Verona Pharma, the World Health Organization (WHO) has approved the name “ensifentrine” as the international non-proprietary name for the company’s RPL554 inhaled PDE3/PDE4 inhibitor, which is in development as both an MDI and… Read more . . .
-
Insys Therapeutics said that a dose finding study of its epinephrine nasal spray that enrolled 49 healthy volunteers demonstrated that one of two doses of the nasal spray tested had a PK profile comparable to… Read more . . .
-
Evoke Pharma said that it has signed a deal with Novos Growth Partners (NGP) for commercialization of its Gimoti metoclopramide nasal spray for the treatment of acute and recurrent diabetic gastroparesis in adult women. Evoke’s… Read more . . .
-
Verona Pharma, which is developing an inhaled PDE3/PDE4 inhibitor, has named Kathleen Rickard as Chief Medical Officer and Tara Rheault as VP of Research and Development Operations and Global Project Management. Rickard has previously served… Read more . . .
-
Liquidia Technologies has announced interim data from the Phase 3 INSPIRE trial of its LIQ861 DPI treprostinil for the treatment of pulmonary arterial hypertension demonstrating that LIQ861 was well-tolerated at doses of up to about… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany